ArticleThe Journal of thoracic and cardiovascular surgery2022
Venovenous extracorporeal membrane oxygenation for patients with refractory coronavirus disease 2019 (COVID-19): Multicenter experience of referral hospitals in a large health care system.
Article in The Journal of thoracic and cardiovascular surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Intracranial hemorrhage in patients treated for SARS-CoV-2 with extracorporeal membrane oxygenation: A systematic review and meta-analysis.Journal of critical care · 2023Pooled it
- Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis.Critical care (London, England) · 2021Pooled it
- Longer Prehospitalization and Preintubation Periods in Intubated Non-survivors and ECMO Patients With COVID-19: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Patient outcomes following extracorporeal membrane oxygenation support for severe COVID-19 acute respiratory distress syndrome.Proceedings (Baylor University. Medical Center) · 2026Article
- Immune-Based Biomarkers as Predictors of Mortality in ECMO Therapy for Severe COVID-19 ARDS: Insights from a Retrospective Study.International journal of molecular sciences · 2025Observational
- Variation in survival in patients with Coronavirus Disease 2019 supported with extracorporeal membrane oxygenation: A multi-institutional analysis of 594 consecutive patients with Coronavirus Disease 2019 supported with extracorporeal membrane oxygenation at 49 hospitals within 21 states.The Journal of thoracic and cardiovascular surgery · 2023Review
- Early mobilization in coronavirus-19 patients treated with extracorporeal membrane oxygenation.Journal of cardiac surgery · 2022Article
- Bloodstream and respiratory coinfections in patients with COVID-19 on ECMO.Journal of cardiac surgery · 2022Article
- Extracorporeal membrane oxygenation for respiratory failure in phases of COVID-19 variants.Journal of cardiac surgery · 2022Article
- Blood Product Utilization in Patients With COVID-19 on ECMO.The Journal of surgical research · 2022Article
- Multi-institutional Analysis of 505 Patients With Coronavirus Disease-2019 Supported With Extracorporeal Membrane Oxygenation: Predictors of Survival.The Annals of thoracic surgery · 2022Review
- Coronavirus 2019 (COVID-19) venovenous extracorporeal oxygenation: Single community hospital results and insights.Journal of cardiac surgery · 2022Article
- Multi-institutional Analysis of 200 COVID-19 Patients Treated With Extracorporeal Membrane Oxygenation: Outcomes and Trends.The Annals of thoracic surgery · 2022Article
- Outcomes of Extracorporeal Membrane Oxygenation in Patients With Severe Acute Respiratory Distress Syndrome Caused by COVID-19 Versus Influenza.The Annals of thoracic surgery · 2022Article
- Treatment of acute respiratory distress syndrome from COVID-19 with extracorporeal membrane oxygenation in obstetrical patients.American journal of obstetrics & gynecology MFM · 2022Article
- Commentary: Extracorporeal membrane oxygenation for patients with refractory Coronavirus Disease 2019 (COVID-19): What do we know and what do we need to learn?The Journal of thoracic and cardiovascular surgery · 2022Article
- Commentary: COVID-19 extracorporeal membrane oxygenation: A long way from home.The Journal of thoracic and cardiovascular surgery · 2022Article
- Commentary: Heroic tales from a national tragedy.The Journal of thoracic and cardiovascular surgery · 2022Article
- Establishing a New ECMO Referral Center Using an ICU-Based Approach: A Feasibility and Safety Study.Healthcare (Basel, Switzerland) · 2022Article
- Extracorporeal membrane oxygenation support during the coronavirus disease 2019 pandemic: Outcomes and technical considerations.JTCVS open · 2021Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe benefit of extracorporeal membrane oxygenation (ECMO) for patients with severe acute respiratory distress from coronavirus disease 2019 refractory to medical management and lung-protective mechanical ventilation has not been adequately determined.
methodsWe reviewed the clinical course of 37 patients with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 infection supported by venovenous ECMO at 4 ECMO referral centers within a large health care system. Patient characteristics, progression of hemodynamics and inflammatory markers, and clinical outcomes were evaluated.
resultsThe patients had median age of 51 years (interquartile range, 40-59), and 73% were male. Peak plateau pressures, vasopressor requirements, and arterial partial pressure of carbon dioxide all improved with ECMO support. In our patient population, 24 of 37 patients (64.8%) survived to decannulation and 21 of 37 patients (56.8%) survived to discharge. Among patients discharged alive from the ECMO facility, 12 patients were discharged to a long-term acute care or rehabilitation facility, 2 were transferred back to the referring hospital for ventilatory weaning, and 7 were discharged directly home. For patients who were successfully decannulated, median length of time on ECMO was 17 days (interquartile range, 10-33.5).
conclusionsVenovenous ECMO represents a useful therapy for patients with refractory severe acute respiratory distress syndrome from coronavirus disease 2019.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.